Matrix metalloproteinases are associated with severity of disease among COVID-19 patients: A possible pharmacological target.
COVID-19
TIMPs
matrix metalloproteinases
Journal
Basic & clinical pharmacology & toxicology
ISSN: 1742-7843
Titre abrégé: Basic Clin Pharmacol Toxicol
Pays: England
ID NLM: 101208422
Informations de publication
Date de publication:
11 Mar 2024
11 Mar 2024
Historique:
revised:
31
01
2024
received:
06
12
2023
accepted:
21
02
2024
medline:
12
3
2024
pubmed:
12
3
2024
entrez:
12
3
2024
Statut:
aheadofprint
Résumé
COVID-19 is a devastating disease and imbalanced matrix metalloproteinase (MMP) activity may contribute to its pathophysiology. This exploratory study examined whether increased circulating concentrations of MMP-2 and MMP-9, and their endogenous inhibitors, the tissue inhibitors of MMP (TIMP)-1, TIMP-2, TIMP-3 and TIMP-4 are persistently found in patients 2 weeks after their recovery from severe or critical COVID-19 as compared with those in healthy controls. Subjects who had severe (n = 26) or critical (n = 25) PCR-confirmed COVID-19 and healthy controls (n = 21) had blood samples drawn 2 weeks after recovery and serum MMP-2, MMP-9, TIMP-1, TIMP-2, TIMP-3 and TIMP-4 were determined using two Human Luminex® Discovery Assays. Circulating MMP activity was also determined by gel zymography. Patients who had severe or critical COVID-19 had increased circulating MMP-9 and MMP-2 concentrations, with increased MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios indicating increased MMP activity, confirmed by gel zymography (all p < 0.05). Higher circulating MMP-9 (but not MMP-2) concentrations were found in critical versus severe COVID-19 (p < 0.05). We found increased circulating MMP-9 and MMP-2 concentrations and activity many days after recovery from the acute disease, with MMP-9 levels associated with disease severity. These biochemical alterations suggest that MMP-2 and MMP-9 may be important pharmacological targets in COVID-19.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Conselho Nacional de Desenvolvimento Científico e Tecnológico
ID : 406442/2022-3
Organisme : Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
ID : Finance Code 001
Informations de copyright
© 2024 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society). Published by John Wiley & Sons Ltd.
Références
Zhou P, Lou YX, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-273. doi:10.1038/S41586-020-2012-7
JHU. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. 2022. Accessed April 7, 2022. https://coronavirus.jhu.edu/map.html
Mohamadian M, Chiti H, Shoghli A, Biglari S, Parsamanesh N, Esmaeilzadeh A. COVID-19: virology, biology and novel laboratory diagnosis. J Gene med. 2021;23(2):e3303. doi:10.1002/JGM.3303
Tajbakhsh A, Gheibi Hayat SM, Taghizadeh H, et al. COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up. Expert Rev Anti Infect Ther. 2021;19(3):345-357. doi:10.1080/14787210.2020.1822737
Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531-538. doi:10.1007/S00392-020-01626-9
Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-436. doi:10.1038/S41586-020-2521-4
Tabrizi ZA, Khosrojerdi A, Aslani S, et al. Multi-facets of neutrophil extracellular trap in infectious diseases: moving beyond immunity. Microb Pathog. 2021;158:158, 105066. doi:10.1016/J.MICPATH.2021.105066
Tang D, Comish P, Kang R. The hallmarks of COVID-19 disease. PLoS Pathog. 2020;16(5):e1008536. doi:10.1371/JOURNAL.PPAT.1008536
Laronha H, Caldeira J. Structure and function of human matrix metalloproteinases. Cell. 2020;9(5):1076. doi:10.3390/CELLS9051076
Castro MM, Tanus-Santos EJ. Inhibition of matrix metalloproteinases (MMPs) as a potential strategy to ameliorate hypertension-induced cardiovascular alterations. Curr Drug Targets. 2013;14(3):335-343. doi:10.2174/138945013804998990
D'Avila-Mesquita C, Couto AES, Campos LCB, et al. MMP-2 and MMP-9 levels in plasma are altered and associated with mortality in COVID'19 patients. Biomed Pharmacother. 2021;142:142, 112067. doi:10.1016/J.BIOPHA.2021.112067
da Silva-Neto PV, Do Valle VB, Fuzo CA, et al. Matrix metalloproteinases on severe COVID-19 lung disease pathogenesis: cooperative actions of MMP-8/MMP-2 axis on immune response through HLA-G shedding and oxidative stress. Biomolecules. 2022;12(5):604. doi:10.3390/BIOM12050604
Kadry R, Newsome AS, Somanath PR. Pharmacological inhibition of MMP3 as a potential therapeutic option for COVID-19 associated acute respiratory distress syndrome. Infect Disord Drug Targets. 2021;21(6):e170721187996. doi:10.2174/1871526520666201116100310
Tveden-Nyborg P, Bergmann TK, Jessen N, Simonsen U, Lykkesfeldt J. BCPT 2023 policy for experimental and clinical studies. Basic Clin Pharmacol Toxicol. 2023;133(4):391-396. doi:10.1111/BCPT.13944
Bonifácio LP, Csizmar VNF, Barbosa-Júnior F, et al. Long-term symptoms among COVID-19 survivors in prospective cohort study, Brazil. Emerg Infect Dis. 2022;28(3):730-733. doi:10.3201/EID2803.212020
World Health Organization. Global COVID-19 Clinical Platform Case Report Form (CRF) for Post COVID condition (Post COVID-19 CRF). Accessed November 29, 2023. https://www.who.int/publications/i/item/global-covid-19-clinical-platform-case-report-form-(crf)-for-post-covid-conditions-(post-covid-19-crf-)
Gerlach RF, Uzuelli JA, Souza-Tarla CD, Tanus-Santos JE. Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal Biochem. 2005;344(1):147-149. doi:10.1016/J.AB.2005.04.038
Belo VA, Souza-Costa DC, Luizon MR, et al. Matrix metalloproteinase-9 genetic variations affect MMP-9 levels in obese children. Int J Obes. 2012;36(1):69-75. doi:10.1038/ijo.2011.169
Demacq C, Vasconcellos VB, Marcaccini AM, Gerlach RF, Machado AA, Tanus-Santos JE. A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretroviral therapy in HIV patients. Pharmacogenomics J. 2009;9(4):265-273. doi:10.1038/TPJ.2009.13
Marson BP, Lacchini R, Belo V, et al. Functional matrix metalloproteinase (MMP)-9 genetic variants modify the effects of hemodialysis on circulating MMP-9 levels. Clin Chim Acta. 2012;414:46-51. doi:10.1016/J.CCA.2012.08.014
Muniz JJ, Lacchini R, Belo VA, et al. Circulating matrix metalloproteinases and their endogenous inhibitors in patients with erectile dysfunction. Int J Impot Res. 2012;24(1):38-43. doi:10.1038/IJIR.2011.44
Van Den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol. 2002;37(6):375-536. doi:10.1080/10409230290771546
Rizzi E, Amaral JH, Guimarães DA, et al. Nitrite treatment downregulates vascular MMP-2 activity and inhibits vascular remodeling in hypertension independently of its antihypertensive effects. Free Radic Biol med. 2019;130:234-243. doi:10.1016/J.FREERADBIOMED.2018.11.002
Unal R, Yao-Borengasser A, Varma V, et al. Matrix metalloproteinase-9 is increased in obese subjects and decreases in response to pioglitazone. J Clin Endocrinol Metab. 2010;95(6):2993-3001. doi:10.1210/JC.2009-2623
Wang J, Jiang M, Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol. 2020;108(1):17-41. doi:10.1002/JLB.3COVR0520-272R
Copaescu A, Smibert O, Gibson A, Phillips EJ, Trubiano JA. The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection. J Allergy Clin Immunol. 2020;146(3):518-534.e1. doi:10.1016/J.JACI.2020.07.001
Wu D, Yang XO. Dysregulation of pulmonary responses in severe COVID-19. Viruses. 2021;13(6):957. doi:10.3390/V13060957
Underwood DC, Osborn RR, Bochnowicz S, et al. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol. 2000;279(5):L895-L902. doi:10.1152/AJPLUNG.2000.279.5.L895
Atkinson JJ, Senior RM. Matrix metalloproteinase-9 in lung remodeling. Am J Respir Cell Mol Biol. 2003;28(1):12-24. doi:10.1165/RCMB.2002-0166TR
Hsu AT, Barrett CD, DeBusk GM, et al. Kinetics and role of plasma matrix metalloproteinase-9 expression in acute lung injury and the acute respiratory distress syndrome. Shock. 2015;44(2):128-136. doi:10.1097/SHK.0000000000000386
Naik SP, Mahesh PA, Jayaraj BS, Madhunapantula SV, Jahromi SR, Yadav MK. Evaluation of inflammatory markers interleukin-6 (IL-6) and matrix metalloproteinase-9 (MMP-9) in asthma. J Asthma. 2017;54(6):584-593. doi:10.1080/02770903.2016.1244828
Yabluchanskiy A, Ma Y, Iyer RP, Hall ME, Lindsey ML. Matrix metalloproteinase-9: many shades of function in cardiovascular disease. Phys Ther. 2013;28(6):391-403. doi:10.1152/PHYSIOL.00029.2013
Cassatella MA, Östberg NK, Tamassia N, Soehnlein O. Biological roles of neutrophil-derived granule proteins and cytokines. Trends Immunol. 2019;40(7):648-664. doi:10.1016/J.IT.2019.05.003
Obradović H, Krstić J, Kukolj T, et al. Doxycycline inhibits IL-17-stimulated MMP-9 expression by downregulating ERK1/2 activation: implications in myogenic differentiation. Mediators Inflamm. 2016;2016:1, 2939658-11. doi:10.1155/2016/2939658
Davey A, McAuley DF, O'Kane CM. Matrix metalloproteinases in acute lung injury: mediators of injury and drivers of repair. Eur Respir J. 2011;38(4):959-970. doi:10.1183/09031936.00032111
Mohammadhosayni M, Sadat Mohammadi F, Ezzatifar F, et al. Matrix metalloproteinases are involved in the development of neurological complications in patients with Coronavirus disease 2019. Int Immunopharmacol. 2021;100:108076. doi:10.1016/J.INTIMP.2021.108076
Duda I, Krzych Ł, Jędrzejowska-Szypułka H, Lewin-Kowalik J. Plasma matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 as prognostic biomarkers in critically ill patients. Open med. 2020;15(1):50-56. doi:10.1515/MED-2020-0008
Gelzo M, Cacciapuoti S, Pinchera B, et al. Matrix metalloproteinases (MMP) 3 and 9 as biomarkers of severity in COVID-19 patients. Sci Rep. 2022;12(1):1212. doi:10.1038/S41598-021-04677-8
Hazra S, Chaudhuri AG, Tiwary BK, Chakrabarti N. Matrix metallopeptidase 9 as a host protein target of chloroquine and melatonin for immunoregulation in COVID-19: a network-based meta-analysis. Life Sci. 2020;257:118096. doi:10.1016/J.LFS.2020.118096
Ueland T, Holter JC, Holten AR, et al. Distinct and early increase in circulating MMP-9 in COVID-19 patients with respiratory failure. J Infect. 2020;81(3):e41-e43. doi:10.1016/J.JINF.2020.06.061
Miesbach W. Pathological role of angiotensin II in severe COVID-19. TH Open. 2020;4(2):e138-e144. doi:10.1055/S-0040-1713678
Osman IO, Melenotte C, Brouqui P, et al. Expression of ACE2, soluble ACE2, angiotensin I, angiotensin II and angiotensin-(1-7) is modulated in COVID-19 patients. Front Immunol. 2021;12. doi:10.3389/FIMMU.2021.625732
Wang C, Qian X, Sun X, Chang Q. Angiotensin II increases matrix metalloproteinase 2 expression in human aortic smooth muscle cells via AT1R and ERK1/2. Exp Biol med (Maywood). 2015;240(12):1564-1571. doi:10.1177/1535370215576312
Oz M, Lorke DE. Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury. Biomed Pharmacother. 2021;136:111193. doi:10.1016/J.BIOPHA.2020.111193
Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69(3):562-573. doi:10.1016/J.CARDIORES.2005.12.002
Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta. 2000;1477(1-2):267-283. doi:10.1016/S0167-4838(99)00279-4
Solun B, Shoenfeld Y. Inhibition of metalloproteinases in therapy for severe lung injury due to COVID-19. Med Drug Discov. 2020;7:100052. doi:10.1016/J.MEDIDD.2020.100052
El-Din AN, Ata KAES, Abdel-Gawad AR, Fahmy NF. Impact of high serum levels of MMP-7, MMP-9, TGF-β and PDGF macrophage activation markers on severity of COVID-19 in obese-diabetic patients. Infect Drug Resist. 2021;14:4015-4025. doi:10.2147/IDR.S329004